John E. Bishop - 28 Feb 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc.

Reporting relationship: SVP, Chief Technology Officer
Issuer ticker: N/A
Reported as of: 28 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2022, 16:14:30 UTC
Prior SEC filing: 15 Jun 2021
Next SEC filing: 14 Oct 2022
Source filing: View source filing
Reporting owner signature: /s/ Jeannette Potts, as Attorney-in-Fact

Key filing fact

John E. Bishop filed Form 4 for Forma Therapeutics Holdings, Inc. on 02 Mar 2022.

Key facts

This page summarizes John E. Bishop's Form 4 filing for Forma Therapeutics Holdings, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2022, 16:14.

Change

Previous filing in this sequence was filed on 15 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FMTX transaction

Common Stock

Award

Transaction value: $0
Shares: +25,950
Change %: +118%
Price: $0.000000
Shares after: 47,950
Date: 28 Feb 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FMTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +38,930
Change %
Price: $0.000000
Shares after: 38,930
Date: 28 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,930
Exercise price: $9.86
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.

Footnote F2

25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.